You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The Promise of Neuroprotective Agents in Parkinson’s Disease
|
|---|---|
| Published in |
Frontiers in Neurology, January 2011
|
| DOI | 10.3389/fneur.2011.00068 |
| Pubmed ID | |
| Authors |
Stacey E. Seidl, Judith A. Potashkin |
| Abstract |
Parkinson's disease (PD) is characterized by loss of dopamine neurons in the substantia nigra of the brain. Since there are limited treatment options for PD, neuroprotective agents are currently being tested as a means to slow disease progression. Agents targeting oxidative stress, mitochondrial dysfunction, and inflammation are prime candidates for neuroprotection. This review identifies Rasagiline, Minocycline, and creatine, as the most promising neuroprotective agents for PD, and they are all currently in phase III trials. Other agents possessing protective characteristics in delaying PD include stimulants, vitamins, supplements, and other drugs. Additionally, combination therapies also show benefits in slowing PD progression. The identification of neuroprotective agents for PD provides us with therapeutic opportunities for modifying the course of disease progression and, perhaps, reducing the risk of onset when preclinical biomarkers become available. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 160 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Australia | 1 | <1% |
| Brazil | 1 | <1% |
| Israel | 1 | <1% |
| India | 1 | <1% |
| Peru | 1 | <1% |
| Mexico | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 152 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 28 | 18% |
| Student > Master | 24 | 15% |
| Student > Bachelor | 18 | 11% |
| Researcher | 13 | 8% |
| Student > Postgraduate | 12 | 8% |
| Other | 32 | 20% |
| Unknown | 33 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 42 | 26% |
| Medicine and Dentistry | 28 | 18% |
| Neuroscience | 14 | 9% |
| Biochemistry, Genetics and Molecular Biology | 9 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
| Other | 25 | 16% |
| Unknown | 35 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 February 2022.
All research outputs
#6,895,954
of 23,098,660 outputs
Outputs from Frontiers in Neurology
#4,363
of 12,015 outputs
Outputs of similar age
#50,822
of 182,032 outputs
Outputs of similar age from Frontiers in Neurology
#12
of 47 outputs
Altmetric has tracked 23,098,660 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 12,015 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 182,032 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.